Literature DB >> 23625073

Interleukin 7 and thymic stromal lymphopoietin: from immunity to leukemia.

Noa Tal1, Chen Shochat, Ifat Geron, Dani Bercovich, Shai Izraeli.   

Abstract

Cancer is often caused by deregulation of normal developmental processes. Here, we review recent research on the aberrant activation of two hematopoietic cytokine receptors in acute lymphoid leukemias. Somatic events in the genes for thymic stromal lymphopoietin and Interleukin 7 receptors as well as in their downstream JAK kinases result in constitutive ligand-independent activation of survival and proliferation in B and T lymphoid precursors. Drugs targeting these receptors or the signaling pathways might provide effective therapies of these leukemias.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23625073     DOI： 10.1007/s00018-013-1337-x

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN： 1420-682X            Impact factor:   9.261


  163 in total

1.  Structural reorganization of the interleukin-7 signaling complex.

Authors:  Craig A McElroy; Paul J Holland; Peng Zhao; Jae-Min Lim; Lance Wells; Edward Eisenstein; Scott T R Walsh
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-30       Impact factor: 11.205

2.  TSLP signaling network revealed by SILAC-based phosphoproteomics.

Authors:  Jun Zhong; Min-Sik Kim; Raghothama Chaerkady; Xinyan Wu; Tai-Chung Huang; Derese Getnet; Christopher J Mitchell; Shyam M Palapetta; Jyoti Sharma; Robert N O'Meally; Robert N Cole; Akinori Yoda; Albrecht Moritz; Marc M Loriaux; John Rush; David M Weinstock; Jeffrey W Tyner; Akhilesh Pandey
Journal:  Mol Cell Proteomics       Date:  2012-02-16       Impact factor: 5.911

3.  Expression of interleukin 7 (IL-7) mRNA and protein in the normal adult human liver: implications for extrathymic T cell development.

Authors:  L Golden-Mason; A M Kelly; O Traynor; G McEntee; J Kelly; J E Hegarty; C O'Farrelly
Journal:  Cytokine       Date:  2001-05-07       Impact factor: 3.861

4.  Impaired immunoglobulin gene rearrangement in mice lacking the IL-7 receptor.

Authors:  A E Corcoran; A Riddell; D Krooshoop; A R Venkitaraman
Journal:  Nature       Date:  1998-02-26       Impact factor: 49.962

5.  Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms.

Authors:  Stephen T Oh; Erin F Simonds; Carol Jones; Matthew B Hale; Yury Goltsev; Kenneth D Gibbs; Jason D Merker; James L Zehnder; Garry P Nolan; Jason Gotlib
Journal:  Blood       Date:  2010-04-19       Impact factor: 22.113

6.  Haploinsufficiency identifies STAT5 as a modifier of IL-7-induced lymphomas.

Authors:  Ninan Abraham; Melissa C Ma; Jonathan W Snow; Melissa Jill Miners; Brian G Herndier; Mark A Goldsmith
Journal:  Oncogene       Date:  2005-08-04       Impact factor: 9.867

7.  Inhibition of gamma delta T cell development and early thymocyte maturation in IL-7 -/- mice.

Authors:  T A Moore; U von Freeden-Jeffry; R Murray; A Zlotnik
Journal:  J Immunol       Date:  1996-09-15       Impact factor: 5.422

8.  Pre-B cell receptor expression is necessary for thymic stromal lymphopoietin responsiveness in the bone marrow but not in the liver environment.

Authors:  Christian A J Vosshenrich; Ana Cumano; Werner Müller; James P Di Santo; Paulo Vieira
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-19       Impact factor: 11.205

9.  Human interleukin 7: molecular cloning and growth factor activity on human and murine B-lineage cells.

Authors:  R G Goodwin; S Lupton; A Schmierer; K J Hjerrild; R Jerzy; W Clevenger; S Gillis; D Cosman; A E Namen
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

10.  Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia.

Authors:  Shannon L Maude; Sarah K Tasian; Tiffaney Vincent; Junior W Hall; Cecilia Sheen; Kathryn G Roberts; Alix E Seif; David M Barrett; I-Ming Chen; J Racquel Collins; Charles G Mullighan; Stephen P Hunger; Richard C Harvey; Cheryl L Willman; Jordan S Fridman; Mignon L Loh; Stephan A Grupp; David T Teachey
Journal:  Blood       Date:  2012-09-06       Impact factor: 22.113
View more
  18 in total

1.  Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein.

Authors:  Haiying Qin; Monica Cho; Waleed Haso; Ling Zhang; Sarah K Tasian; Htoo Zarni Oo; Gian Luca Negri; Yongshun Lin; Jizhong Zou; Barbara S Mallon; Shannon Maude; David T Teachey; David M Barrett; Rimas J Orentas; Mads Daugaard; Poul H B Sorensen; Stephan A Grupp; Terry J Fry
Journal:  Blood       Date:  2015-06-03       Impact factor: 22.113

Review 2.  Modular nanotransporters for targeted intracellular delivery of drugs: folate receptors as potential targets.

Authors:  Tatiana A Slastnikova; Andrey A Rosenkranz; Michael R Zalutsky; Alexander S Sobolev
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

Review 3.  Stem and progenitor cell dysfunction in human trisomies.

Authors:  Binbin Liu; Sarah Filippi; Anindita Roy; Irene Roberts
Journal:  EMBO Rep       Date:  2014-12-17       Impact factor: 8.807

4.  Adult T-cell acute lymphoblastic leukemias with IL7R pathway mutations are slow-responders who do not benefit from allogeneic stem-cell transplantation.

Authors:  Rathana Kim; Nicolas Boissel; Aurore Touzart; Thibaut Leguay; Florian Thonier; Xavier Thomas; Emmanuel Raffoux; Françoise Huguet; Patrick Villarese; Cécile Fourrage; Loïc Passini; Mathilde Hunault; Stéphane Lepretre; Patrice Chevallier; Thorsten Braun; Véronique Lhéritier; Sylvain Chantepie; Sébastien Maury; Martine Escoffre; Emmanuelle Tavernier; Yves Chalandon; Carlos Graux; Elizabeth Macintyre; Norbert Ifrah; Vahid Asnafi; Hervé Dombret; Ludovic Lhermitte
Journal:  Leukemia       Date:  2020-01-28       Impact factor: 11.528

5.  Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome.

Authors:  Omer Schwartzman; Angela Maria Savino; Michael Gombert; Chiara Palmi; Gunnar Cario; Martin Schrappe; Cornelia Eckert; Arend von Stackelberg; Jin-Yan Huang; Michal Hameiri-Grossman; Smadar Avigad; Geertruy Te Kronnie; Ifat Geron; Yehudit Birger; Avigail Rein; Giulia Zarfati; Ute Fischer; Zohar Mukamel; Martin Stanulla; Andrea Biondi; Giovanni Cazzaniga; Amedeo Vetere; Bridget K Wagner; Zhu Chen; Sai-Juan Chen; Amos Tanay; Arndt Borkhardt; Shai Izraeli
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-01       Impact factor: 11.205

Review 6.  Therapeutic targeting of IL-7Rα signaling pathways in ALL treatment.

Authors:  Sarah D Cramer; Peter D Aplan; Scott K Durum
Journal:  Blood       Date:  2016-06-06       Impact factor: 22.113

7.  On mice and humans: the role of thymic stromal lymphopoietin in human B-cell development and leukemia.

Authors:  Angela Maria Savino; Shai Izraeli
Journal:  Haematologica       Date:  2016-04       Impact factor: 9.941

8.  New anti-IL-7Rα monoclonal antibodies show efficacy against T cell acute lymphoblastic leukemia in pre-clinical models.

Authors:  Julie A Hixon; Caroline Andrews; Lila Kashi; Casey L Kohnhorst; Emilee Senkevitch; Kelli Czarra; Joao T Barata; Wenqing Li; Joel P Schneider; Scott T R Walsh; Scott K Durum
Journal:  Leukemia       Date:  2019-08-22       Impact factor: 11.528

9.  Immunoregulation by IL-7R-targeting antibody-drug conjugates: overcoming steroid-resistance in cancer and autoimmune disease.

Authors:  Masahiro Yasunaga; Shino Manabe; Yasuhiro Matsumura
Journal:  Sci Rep       Date:  2017-09-06       Impact factor: 4.379

10.  Down-regulation of interleukin 7 receptor (IL-7R) contributes to central nervous system demyelination.

Authors:  Xudan Lei; Shijiao Cai; Yang Chen; Jianlin Cui; Yajie Wang; Zongjin Li; Yuhao Li
Journal:  Oncotarget       Date:  2017-04-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.